Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies

NCT03151057 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

16

Enrollment

OTHER

Sponsor class

Stopped Safety endpointreached

Conditions

B Cells-Tumors
B Cell Chronic Lymphocytic Leukemia
Follicular Lymphoma
Mantle Cell Lymphoma
Large B-Cell Diffuse Lymphoma of Bone (Diagnosis)

Interventions

DRUG: Idelalisib 100 MG
DRUG: Placebo Oral Tablet

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]